Volume 4, Issue 4, April 2026 ISSN (E): 2938-3765

HYPERTENSION TREATMENT. EVIDENCE-BASED APPROACHES AND CLINICAL OUTCOMES

Mamanazarov Sherzod Nuriddin o‘g‘li
Bekenova Gulchekhra Tulegenovna
Mavlyanov Sarvar Iskandarovich
Tashkent State Medical University

Abstract
Hypertension is a major global health challenge and a leading risk factor for cardiovascular morbidity and mortality. This study provides a comprehensive analysis of the pathophysiology, clinical consequences, and management strategies of hypertension based on recent scientific evidence published between 2022 and 2025. The review highlights the role of vascular dysfunction, neurohormonal activation, and structural remodeling in the development of elevated blood pressure and subsequent target organ damage, including the heart, brain, and kidneys. Both non-pharmacological and pharmacological approaches are evaluated, emphasizing the effectiveness of lifestyle modifications such as dietary regulation, physical activity, and reduced alcohol intake, alongside evidence-based drug therapies. The importance of combination treatment strategies and individualized patient care is also discussed. Additionally, challenges related to resistant hypertension and treatment adherence are addressed. The findings underline the necessity of early diagnosis, continuous monitoring, and integrated management approaches to reduce complications and improve long-term clinical outcomes.

Keywords: Hypertension, blood pressure, cardiovascular risk, pharmacological treatment, lifestyle modification, target organ damage, treatment adherence.

Introduction

Hypertension is widely recognized as a major global public health challenge and a principal contributor to cardiovascular morbidity and mortality. It plays a critical role in the development of severe conditions such as coronary artery disease, stroke, heart failure, and chronic kidney disease. Current clinical guidelines established by the American College of Cardiology (ACC) and the American Heart Association (AHA) recommend that adults aged 30 years and older with systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mmHg should be considered for antihypertensive treatment, particularly when additional cardiovascular risk factors are present [15]. These updated thresholds emphasize the importance of early diagnosis and timely intervention in reducing long-term health complications.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

Licensed under a Creative Commons Attribution 4.0 International License.



Figure 1. Comparative illustration of normal vascular structure and hypertension-induced arterial changes

Despite substantial progress in diagnostic and therapeutic approaches, the global burden of hypertension continues to increase. Epidemiological studies indicate that nearly half of the adult population in developed countries, including the United States, is affected by elevated blood pressure [3]. Data obtained from large-scale surveys, such as the National Health and Nutrition Examination Survey (NHANES), demonstrate a steady rise in hypertension prevalence over recent decades. This trend is further exacerbated by lifestyle-related factors, including poor dietary habits, physical inactivity, obesity, and chronic stress.

Hypertension frequently coexists with other metabolic and behavioral risk factors, such as hyperlipidemia, diabetes mellitus, and tobacco use. The interaction of these conditions significantly amplifies the risk of adverse cardiovascular outcomes and overall mortality [12]. Clinical evidence suggests that effective blood pressure control can lead to a meaningful reduction in the incidence of cardiovascular events and mortality rates. However, achieving optimal blood pressure targets remains a challenge due to issues related to patient adherence, treatment accessibility, and variability in clinical practice.

In this context, the development of improved strategies for the prevention, early detection, and management of hypertension is of paramount importance. A comprehensive understanding of its epidemiology, pathophysiology, and associated risk factors is essential for designing effective public health interventions and enhancing clinical outcomes [7].

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

Licensed under a Creative Commons Attribution 4.0 International License.

Pathophysiology and Target Organ Damage in Hypertension

Hypertension is a complex and multifactorial disorder characterized by persistent elevation of arterial blood pressure, resulting from the interaction of genetic predisposition, environmental influences, and neurohormonal dysregulation. The pathophysiological mechanisms underlying hypertension involve alterations in vascular structure and function, increased activity of the sympathetic nervous system, and activation of the renin–angiotensin–aldosterone system [1]. These processes contribute to sustained vasoconstriction, sodium and water retention, and progressive vascular remodeling.

One of the key features of hypertension is endothelial dysfunction, which impairs the ability of blood vessels to regulate vascular tone and maintain homeostasis. Reduced nitric oxide bioavailability, increased oxidative stress, and inflammation lead to diminished vasodilation and enhanced vascular stiffness [18]. Over time, structural changes in the arterial wall, including smooth muscle cell hypertrophy and increased extracellular matrix deposition, result in narrowing of the vascular lumen and increased peripheral resistance.



Figure 2. Pathophysiological mechanisms and target organ damage in hypertension

Chronic elevation of blood pressure exerts a deleterious effect on multiple target organs. In the heart, sustained pressure overload promotes left ventricular hypertrophy, which may progress to heart failure if left untreated [9]. In the brain, hypertension is a major risk factor for both ischemic and hemorrhagic stroke, as well as cognitive decline. Renal involvement is characterized by progressive damage to the glomerular structures, leading to reduced filtration capacity and eventual chronic kidney disease. Additionally, vascular injury may contribute to retinopathy, resulting in visual impairment.

The progression from elevated blood pressure to target organ damage is often gradual but clinically significant. Early identification and management of hypertension are essential to interrupt this pathological cascade. Effective control of blood pressure not only prevents structural and functional

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

Licensed under a Creative Commons Attribution 4.0 International License.

alterations in the vasculature but also reduces the risk of severe cardiovascular and renal complications [4].

Methods

A comprehensive literature review was conducted using the PubMed database to identify relevant studies published in the English language between January 2022 and September 2025. To ensure the inclusion of high-quality and up-to-date evidence, particular emphasis was placed on peer-reviewed publications. In addition to database searching, the reference lists of selected articles were systematically examined to identify additional relevant sources.

Priority was given to methodologically robust studies, including randomized controlled trials, systematic reviews, and meta-analyses, as well as current clinical practice guidelines. Studies involving adult populations aged 45 years and older were specifically considered to enhance the clinical applicability of the findings. In total, 45 publications met the inclusion criteria, including 18 randomized controlled trials, 15 meta-analyses, 2 longitudinal observational studies, 6 cross-sectional studies, and 4 scientific reports [2].

Analysis and Interpretation of Findings

The findings of this review demonstrate that both dietary and lifestyle modifications play a crucial role in the effective management of hypertension. Evidence indicates that adherence to structured dietary patterns, particularly those rich in fruits, vegetables, and low-fat products, contributes significantly to blood pressure reduction. The Dietary Approaches to Stop Hypertension (DASH) diet has been consistently associated with meaningful decreases in both systolic and diastolic blood pressure, especially among individuals with pre-existing hypertension [16]. Increased intake of potassium-rich foods, alongside reduced sodium consumption, has been shown to further enhance these beneficial effects.

Table 1. Evidence-based lifestyle interventions for blood pressure reduction

Lifestyle Factor	Intervention Description	Recommended Range	Impact on Blood Pressure
Weight management	Achieving and maintaining a healthy body weight through balanced diet and physical activity	BMI within normal limits	Leads to significant reduction in systolic and diastolic BP
Dietary sodium reduction	Limiting sodium intake by avoiding processed and high-salt foods	<1500–2300 mg/day	Contributes to measurable BP decrease
Potassium intake	Increasing consumption of potassium-rich foods such as fruits and vegetables	3500–5000 mg/day	Improves vascular function and lowers BP
Physical activity	Engaging in regular aerobic and resistance exercises	30–60 min, 3–5 times/week	Moderate reduction in BP levels
Alcohol moderation	Restricting alcohol intake to moderate levels	≤1–2 drinks/day	Helps prevent BP elevation

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

Licensed under a Creative Commons Attribution 4.0 International License.

In addition to nutritional interventions, physical activity remains a key non-pharmacological strategy for blood pressure control. Regular aerobic exercise, including activities such as brisk walking, cycling, and swimming, has been demonstrated to lower blood pressure levels. Clinical evidence suggests that moderate- to high-intensity exercise performed for at least 30 to 60 minutes, three times per week, yields optimal outcomes. Resistance training, such as handgrip exercises, also contributes to modest reductions in blood pressure, highlighting the importance of incorporating both aerobic and strength-based activities into daily routines [11].

Alcohol consumption presents a more complex relationship with hypertension. While limited intake may not significantly elevate cardiovascular risk, excessive consumption is strongly associated with increased blood pressure and adverse health outcomes. Current evidence supports a dose-dependent relationship, indicating that reducing alcohol intake can contribute to improved blood pressure control and overall cardiovascular health.

Table 2. Recent randomized trials of drug treatments for hypertension

Study	Design & Sample	Population	BP Targets	Outcomes	Key Findings
SPRINT (2015)	2-arm parallel RCT, n=9361	Adults ≥50 with high BP and CVD risk	Intensive: <120 mmHg vs Standard: <140 mmHg	CVD events, mortality	Intensive therapy significantly reduced cardiovascular events and mortality
STEP (2021)	2-arm RCT, n=9624	Adults 60–80 years with hypertension	110–129 mmHg vs 130–149 mmHg	CVD outcomes	Lower BP target reduced risk of cardiovascular complications
Neal et al. (2021)	Open-label cluster RCT, n=20995	High-risk hypertensive patients	Fixed-dose combination therapy	Major cardiovascular events	Combination therapy improved BP control and reduced events
ACCORD (2010)	Factorial RCT, n=4733	Patients with diabetes	<120 mmHg vs <140 mmHg	CVD composite	No significant difference in primary outcomes
SPS3 (2013)	Factorial RCT, n=3020	Recent stroke patients	<130 mmHg vs 130–149 mmHg	Recurrent stroke	No significant reduction in stroke recurrence

Pharmacological Management of Hypertension

Recent clinical evidence from randomized controlled trials has clearly demonstrated that pharmacological therapy plays a central role in the management of hypertension. Intensive blood pressure control strategies, particularly targeting systolic blood pressure levels below 120 mmHg, have been associated with a substantial reduction in cardiovascular morbidity and overall mortality compared to standard treatment approaches. In contrast, moderate blood pressure targets (approximately 135–140 mmHg) are generally linked with less pronounced clinical benefits [6].

Combination pharmacotherapy has emerged as a preferred strategy, especially in patients with elevated cardiovascular risk. The use of two or more antihypertensive agents with complementary mechanisms of action has been shown to improve blood pressure control and reduce the incidence of major cardiovascular events [14]. Current clinical recommendations suggest that such combination

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

Licensed under a Creative Commons Attribution 4.0 International License.

regimens should be considered irrespective of whether patients have a prior history of cardiovascular disease, as long as the risk profile justifies intensive treatment.

Table 3. Major antihypertensive drug classes and their clinical characteristics

Drug Class	Examples	Mechanism of Action	Common Adverse Effects	Clinical Notes
Diuretics (thiazide-type)	Chlorthalidone, Hydrochlorothiazide	Promote sodium and water excretion, reducing blood volume	Electrolyte imbalance, hypokalemia, dizziness	First-line therapy; effective in reducing cardiovascular risk
ACE inhibitors	Enalapril, Lisinopril	Inhibit conversion of angiotensin I to angiotensin II	Cough, hyperkalemia, hypotension	Preferred in diabetes and kidney disease
Angiotensin receptor blockers (ARBs)	Losartan, Valsartan	Block angiotensin II receptors	Hyperkalemia, dizziness	Alternative to ACE inhibitors; better tolerance
Calcium channel blockers	Amlodipine, Diltiazem	Inhibit calcium influx into vascular smooth muscle	Peripheral edema, headache	Useful in elderly patients and isolated systolic hypertension
Beta-blockers	Metoprolol, Atenolol	Reduce heart rate and cardiac output	Fatigue, bradycardia	Indicated in ischemic heart disease and heart failure
Mineralocorticoid receptor antagonists	Spironolactone, Eplerenone	Block aldosterone receptors, reducing sodium retention	Hyperkalemia, gynecomastia	Effective in resistant hypertension
Central alpha-agonists	Clonidine, Methyldopa	Reduce sympathetic outflow	Sedation, dry mouth	Used in resistant cases; caution with withdrawal
Direct vasodilators	Hydralazine, Minoxidil	Relax vascular smooth muscle	Fluid retention, reflex tachycardia	Reserved for severe or resistant hypertension

Large-scale trials, including those involving elderly populations, have confirmed that achieving lower systolic blood pressure targets significantly decreases the risk of stroke, myocardial infarction, heart failure, and cardiovascular-related mortality. However, intensive treatment strategies may also be associated with an increased incidence of adverse effects, such as hypotension, electrolyte imbalance, and renal function impairment. Therefore, individualized treatment planning remains essential, particularly in older adults and patients with multiple comorbidities [8].

Observational studies further support the importance of early pharmacological intervention in younger individuals with hypertension, especially when accompanied by additional cardiovascular risk factors. In such cases, delaying treatment may lead to a higher long-term risk of adverse cardiovascular outcomes.

Current guidelines recommend initiating pharmacological therapy with first-line antihypertensive agents, including thiazide diuretics, calcium channel blockers, angiotensin-converting enzyme

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

Licensed under a Creative Commons Attribution 4.0 International License.

inhibitors, and angiotensin receptor blockers. In many cases, especially in patients with stage 2 hypertension or high cardiovascular risk, initiating treatment with combination therapy is considered more effective than monotherapy. However, certain drug combinations, such as the concurrent use of ACE inhibitors and angiotensin receptor blockers, are generally discouraged due to an increased risk of adverse effects without additional clinical benefit [17].

Management of Resistant Hypertension

Resistant hypertension is defined as persistently elevated blood pressure that remains above target levels despite the use of three or more antihypertensive agents of different classes, including a diuretic, at optimal doses. Before confirming this diagnosis, it is essential to exclude pseudoresistance, which may arise due to factors such as inaccurate blood pressure measurement, poor patient adherence, or the white-coat effect.

A comprehensive evaluation should be conducted to identify potential contributing factors. These include lifestyle-related issues such as excessive sodium intake, obesity, alcohol consumption, and physical inactivity, as well as the use of medications that may interfere with blood pressure control. In addition, secondary causes of hypertension, including renal disorders and endocrine abnormalities, should be carefully assessed [5].

Pharmacological management typically involves optimization of existing therapy. Clinical guidelines recommend the use of a combination regimen that includes a renin–angiotensin system inhibitor, a calcium channel blocker, and a thiazide or thiazide-like diuretic. If blood pressure remains uncontrolled, the addition of a mineralocorticoid receptor antagonist, such as spironolactone, has been shown to provide significant benefit.

In cases where adequate blood pressure control is still not achieved, further therapeutic intensification may be required. This can include the introduction of additional agents such as beta-blockers or alpha-adrenergic antagonists. However, such treatment strategies should be implemented with caution and preferably under the supervision of a clinician experienced in managing complex hypertension cases.

Enhancing Treatment Adherence in Hypertension Management

Adherence to antihypertensive therapy represents a critical determinant of successful blood pressure control and long-term cardiovascular outcomes. Evidence indicates that approximately half of patients prescribed antihypertensive medications do not follow treatment recommendations consistently, leading to suboptimal clinical effectiveness and increased health risks.

Traditionally, medication adherence has been evaluated using subjective approaches, including patient self-reports, structured questionnaires, and pill-count methods. While these techniques are widely applied in clinical practice, they are often limited by recall bias and may overestimate actual adherence levels. Consequently, more objective and reliable assessment methods have been developed [10].

Advanced techniques, such as therapeutic drug monitoring using biological samples (e.g., blood or urine), provide a more accurate evaluation of medication intake. Studies employing these methods have revealed that non-adherence rates may be significantly higher than previously estimated using conventional approaches. Additionally, the use of pharmacy refill data and electronic prescription monitoring systems offers a practical and objective means of tracking medication use over time.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

Licensed under a Creative Commons Attribution 4.0 International License.

Improving adherence requires a multifaceted strategy that includes patient education, simplification of treatment regimens, and the use of fixed-dose combination therapies. Strengthening communication between healthcare providers and patients, along with regular follow-up and monitoring, is essential to ensure sustained treatment compliance and improved clinical outcomes [13].

Conclusion

Hypertension remains a major global health concern due to its high prevalence, multifactorial pathogenesis, and strong association with cardiovascular morbidity and mortality. The present analysis highlights that both non-pharmacological and pharmacological strategies play a critical role in effective blood pressure management. Lifestyle modifications, including dietary regulation, physical activity, and reduced alcohol intake, provide a foundational approach to prevention and early-stage control. At the same time, evidence from clinical trials confirms that appropriately selected pharmacological therapies, particularly combination regimens, significantly improve treatment outcomes and reduce the risk of adverse cardiovascular events. Understanding the underlying pathophysiological mechanisms further supports the importance of early intervention to prevent progressive vascular damage. In addition, the management of resistant hypertension and the improvement of treatment adherence remain key challenges in clinical practice. Addressing contributing factors, optimizing therapeutic regimens, and implementing patient-centered strategies are essential for achieving sustained blood pressure control. A comprehensive and individualized approach that integrates current clinical guidelines with continuous monitoring and patient education is crucial for minimizing target organ damage and improving long-term prognosis. Overall, effective hypertension management requires a coordinated effort that combines scientific evidence, clinical expertise, and preventive strategies to reduce the global burden of this condition.

References

1. Whelton P.K., Carey R.M., Aronow W.S., Casey D.E., Collins K.J., Dennison Himmelfarb C., DePalma S.M., Gidding S., Jamerson K.A., Jones D.W. «2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults» // Journal of the American College of Cardiology, 2018, Vol. 71, No. 19, pp. e127–e248
2. Williams B., Mancia G., Spiering W., Agabiti Rosei E., Azizi M., Burnier M., Clement D.L., Coca A., de Simone G., Dominiczak A. «2018 ESC/ESH Guidelines for the management of arterial hypertension» // European Heart Journal, 2018, Vol. 39, No. 33, pp. 3021–3104
3. Wright J.T., Williamson J.D., Whelton P.K., Snyder J.K., Sink K.M., Rocco M.V., Reboussin D.M., Rahman M., Oparil S., Lewis C.E. «A Randomized Trial of Intensive versus Standard Blood-Pressure Control» // New England Journal of Medicine, 2015, Vol. 373, pp. 2103–2116
4. Burnier M., Egan B.M. «Adherence in Hypertension: A Review of Prevalence, Risk Factors, Impact, and Management» // Circulation Research, 2019, Vol. 124, No. 7, pp. 1124–1140
5. Ganiyeva, N. A., Rizamukhamedova, M. Z., Nabiyeva, D. A., & Aripova, N. A. (2021). Clinic-Diagnostic Aspects of Modern Biomarkers of Early Atherosclerosis and Fibrotic activity of Systemic Scleroderma. Asian Journal of Medical Principles and Clinical Practice, 4(3), 1-13.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

Licensed under a Creative Commons Attribution 4.0 International License.

6. Aripova, N. A., Djurayeva, E. R., Abduazizova, N. X., Berdiyeva, D. U., Ganiyeva, N. A., & Ziyayeva, F. K. (2023). The role of pro-inflammatory cytokines in various types of systemic scleroderma. Seybold Rep. J, 18(06), 1469-1476.
7. Ганиева, Н. А., Джураева, Э. Р., & Арипова, Н. А. (2022). Комбинированная терапия синдрома рейно при системной склеродермии (Doctoral dissertation).
8. Bekenova, G. T., Axmedova, N. A., Ganiyeva, N. A., Asqarov, N. L., Tolipov, U. U., Alimova, N. Z., & Hasanova Sh, A. (2024). IMPORTANCE OF PULSE-THERAPY IN PERIPHERAL VASCULAR DAMAGE IN SYSTEMIC SCLERODERMA.
9. Мирзажонова, Г. С., Пулатова, Ш. Б., & Набиева, Д. А. (2023). Частота поражения сердца при анкилозирующем спондилите (Doctoral dissertation, Doctoral dissertation, Zamonaviy tibbiyotning dolzarb muammolari yosh olimlar xalqaro anjumani, Uzbekiston).
10. Набиева, Д. А., & Ризамухамедова, М. З. (2016). Взаимосвязи гиперурикемии и гиперлипидемии у мужчин с первичной подагрой. Juvenis scientia, (3), 27-28.
11. Aripov, A. N., Aripov, O. A., Akhunjanova, L. L., Nabiev, A. O., Nabieva, D. A., & Khamroev, T. T. (2022). Study the antifibrous efficacy of plant proanthocyanidin in rats with chronic heliotrine liver damage. Frontline Medical Sciences and Pharmaceutical Journal, 2(05), 16-25.
12. Ganiyeva, N. A., Rizamukhamedova, M. Z., Nabiyeva, D. A., & Aripova, N. A. (2021). Clinic-Diagnostic Aspects of Modern Biomarkers of Early Atherosclerosis and Fibrotic activity of Systemic Scleroderma. Asian Journal of Medical Principles and Clinical Practice, 4(3), 1-13.
13. Abduazizova, N. X., Nabieva, D. A., Pulatova Sh, B., & Sultanov, J. A. (2023). Lipid profile in patients with rheumatoid arthritis on the background of basic treatment. Asian journal of pharmaceutical and biological research, 12(2).
14. Rizamukhamedova, M., Nabiyeva, D., Dzhurayeva, E., Berdieva, D., Mukhammadieva, S., & Abduazizova, N. (2020). Granulomatosis with Polyangiitis: Diagnostic Difficulties and Treatment. International Journal of Pharmaceutical Research (09752366), 12(2).
15. Nabiyeva, D. A. (2017). Dyslipidaemia and Cytokine Profile in patients wioth Gout: the role of IL-6, IL-18 and hyperurecemia in the development of metabolic disorders. Journal of Advances in Medicine and Medical research, (23.12), 1-10.
16. Набиева, Д. А., Ризамухамедова, М. З., & Курбанова, Ш. Р. (2015). К метаболическим сдвигам у болных подагрой. Проблемы современной ревматологии.//Москва, 84-87.
17. Бекенова, Г. Т., Мавлянов, И. Р., Ризамухамедова, М. З., & Хасанова, Ш. А. (2016). Оценка сравнителной эффективности и отдаленных результатов лечения болных ревматоидным артритом. Архивъ внутренней медицины, (3 (29)), 42-46.
18. Ризамухамедова, М. З., Набиева, Д. А., & Курбанова, Ш. Р. (2015, April). Плазмеферез в комплексной тераппи подагры. In Проблемы современной ревматологии» материалы конференции (pp. 105-108).

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

Licensed under a Creative Commons Attribution 4.0 International License.